How many clinical trials are studying Rimegepant?

5 recruiting trials in our tracked data involve Rimegepant.

What conditions is Rimegepant being studied for?

In our tracked recruiting trials, Rimegepant is being studied in trials for Migraine, Acute Treatment of Migraine, Menstrual Migraine.

Rimegepant: clinical trials recruiting now

Q: Is Rimegepant FDA-approved?

Yes. According to the FDA drug label available through openFDA, Rimegepant is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Rimegepant appears in the FDA drug-label database. Marketed as NURTEC ODT.

FDA-approved use

NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: acute treatment of migraine with or without aura in adults ( 1.1 ) preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.

FDA recalls / enforcement

Reason (FDA)	Classification	Status	Initiated
CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Cardinal Health Inc.	Class II (FDA: may cause temporary or reversible harm)	Terminated	2021-03-15

FDA label via openFDA

Phase breakdown

Phase 3 2 Phase 4 2 Not applicable 1

Conditions being studied

Condition	Trials
Migraine · Rimegepant for Migraine	5
Acute Treatment of Migraine	1
Menstrual Migraine	1

Recruiting trials involving Rimegepant

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
NCT06473597 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
NCT07609914 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 123 locations
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 93 locations
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
NCT05046613 · Phase: Not specified · Ages: 0 Years and older · Sex: Female · 1 location

Common questions

Is Rimegepant FDA-approved?

Yes, marketed as NURTEC ODT.

How many recruiting trials involve Rimegepant?

5 recruiting trials across 3 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.